Abstract

Granisetron 0.05-mg/mL Oral Suspension

Author(s): Allen Loyd V Jr

Issue: May/Jun 2006 - Hormone Replacement Therapy

Page(s): 222

Download in electronic PDF format for $75
  • Granisetron 0.05-mg/mL Oral Suspension Page 1

Abstract

A formulation for preparing Granisetron 0.05-mg/mL Oral Suspension. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • granisetron
  • nausea
  • vomiting
  • antiemetic agent
  • cancer chemotherapy
  • radiation therapy
  • selective 5-hydroxytryptamine 3 receptor antagonist
  • selective 5-HT3 blocker

Related Categories

  • CANCER AND AIDS
  • FORMULATIONS
  • GASTROENTEROLOGY
  • ADVERSE DRUG EVENTS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2006
Pg. 222
Granisetron 0.05-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2011
Pg. 419
Granisetron Hydrochloride 0.2-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Jan/Feb 2013
Pg. 66
Granisetron 1-mg/mL Injection
Author(s): Allen Loyd V Jr
Jan/Feb 2018
Pg. 86-94
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride
Author(s): Wu George, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly
Nov/Dec 2022
Pg. 513
Granisetron Hydrochloride 005 mg/mL in Ora-Sweet and Ora-Plus
Author(s): Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312
Wetting and/or Solubilizing Agents, Featured Excipient:
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Jul/Aug 2000
Pg. 250-251
Nausea and Vomiting in Hospice Patients
Author(s): Boomsma Diane
Mar/Apr 2004
Pg. 126-129
Basics of Compounding for the Treatment of Warts
Author(s): Allen Loyd V Jr
Mar/Apr 2008
Pg. 156-160
Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration
Author(s): Trusley Craig, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2021
Pg. 500
Domperidone 5 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jan/Feb 2018
Pg. 76-85
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection
Author(s): Wu George, Powers Dan, Yeung Stanley, Chen Frank
Mar/Apr 2008
Pg. 170-173
Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Author(s): Kupiec Thomas C, Ben Michel, Trusley Craig, Trissel Lawrence A
Jul/Aug 2012
Pg. 339
Ondansetron Hydrochloride 2-mg/mL Injection
Author(s): Allen Loyd V Jr
Sep/Oct 2008
Pg. 460-462
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration
Author(s): Ben Michel, Kupiec Thomas C, Trusley Craig, Trissel Lawrence A
Jan/Feb 2017
Pg. 66-75
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate
Author(s): Wu George, Yeung Stanley, Chen Frank
Jan/Feb 2017
Pg. 76-82
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride
Author(s): Wu George, Yeung Stanley, Chen Frank
Nov/Dec 2004
Pg. 462-465
Basics of Compounding for Cough
Author(s): Allen Loyd V Jr
Jul/Aug 2019
Pg. 316
Domperidone 5 mg/mL in Oral Mix
Author(s): Allen Loyd V Jr
Jul/Aug 2002
Pg. 255-256
Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women
Author(s): Mason Dave